IL102769A - Piperidine derivatives are converted in positions 4,2,1, their preparation and pharmaceutical preparations containing them - Google Patents
Piperidine derivatives are converted in positions 4,2,1, their preparation and pharmaceutical preparations containing themInfo
- Publication number
- IL102769A IL102769A IL10276992A IL10276992A IL102769A IL 102769 A IL102769 A IL 102769A IL 10276992 A IL10276992 A IL 10276992A IL 10276992 A IL10276992 A IL 10276992A IL 102769 A IL102769 A IL 102769A
- Authority
- IL
- Israel
- Prior art keywords
- piperidinamine
- benzyl
- dimethylbenzoyl
- salt
- quinolylmethyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, ***e
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH237491 | 1991-08-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
IL102769A0 IL102769A0 (en) | 1993-01-31 |
IL102769A true IL102769A (en) | 1999-01-26 |
Family
ID=4232283
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL10276992A IL102769A (en) | 1991-08-12 | 1992-08-10 | Piperidine derivatives are converted in positions 4,2,1, their preparation and pharmaceutical preparations containing them |
IL11875096A IL118750A0 (en) | 1991-08-12 | 1996-06-27 | 1-Acylpiperidine compounds |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL11875096A IL118750A0 (en) | 1991-08-12 | 1996-06-27 | 1-Acylpiperidine compounds |
Country Status (23)
Country | Link |
---|---|
US (3) | US5310743A (zh) |
EP (1) | EP0532456B1 (zh) |
JP (1) | JP3118090B2 (zh) |
KR (1) | KR100261367B1 (zh) |
AT (1) | ATE120456T1 (zh) |
AU (1) | AU660180B2 (zh) |
CA (1) | CA2075684C (zh) |
DE (1) | DE59201771D1 (zh) |
DK (1) | DK0532456T3 (zh) |
ES (1) | ES2070617T3 (zh) |
FI (1) | FI104631B (zh) |
GR (1) | GR3015954T3 (zh) |
HU (1) | HU221305B1 (zh) |
IL (2) | IL102769A (zh) |
MX (1) | MX9204627A (zh) |
MY (1) | MY110227A (zh) |
NO (2) | NO303448B1 (zh) |
NZ (1) | NZ243888A (zh) |
PH (1) | PH29963A (zh) |
RU (1) | RU2114829C1 (zh) |
SA (1) | SA94140632A (zh) |
TW (1) | TW204342B (zh) |
ZA (1) | ZA926013B (zh) |
Families Citing this family (106)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE116640T1 (de) * | 1992-03-13 | 1995-01-15 | Bio Mega Boehringer Ingelheim | Substituierte pipecoline-säurederivate als hiv- protease-hemmer. |
FR2700472B1 (fr) | 1993-01-19 | 1995-02-17 | Rhone Poulenc Rorer Sa | Association synergisante ayant un effet antagoniste des récepteurs NK1 et NK2. |
DE69430861T2 (de) * | 1993-04-07 | 2003-01-23 | Otsuka Pharma Co Ltd | N-acylierte 4-aminopiperidin derivate als aktive bestandteile von peripher gefässerweiternden wikstoffen |
US5883098A (en) * | 1993-11-29 | 1999-03-16 | Fujisawa Pharmaceutical Co., Ltd. | Piperazine derivatives |
IL111730A (en) * | 1993-11-29 | 1998-12-06 | Fujisawa Pharmaceutical Co | Piperazine derivatives, processes for their preparation and pharmaceutical preparations containing them |
US5610165A (en) * | 1994-02-17 | 1997-03-11 | Merck & Co., Inc. | N-acylpiperidine tachykinin antagonists |
US5935951A (en) * | 1994-09-30 | 1999-08-10 | Novartis Finance Corporation | 1-acyl-4-aliphatylaminopiperidine compounds |
TW397825B (en) * | 1994-10-14 | 2000-07-11 | Novartis Ag | Aroyl-piperidine derivatives |
FR2728166A1 (fr) | 1994-12-19 | 1996-06-21 | Oreal | Composition topique contenant un antagoniste de substance p |
FR2728165A1 (fr) | 1994-12-19 | 1996-06-21 | Oreal | Utilisation d'un antagoniste de substance p pour le traitement des rougeurs cutanees d'origine neurogene |
FR2728169A1 (fr) | 1994-12-19 | 1996-06-21 | Oreal | Utilisation d'un antagoniste de substance p pour le traitement des prurits et des dysesthesies oculaires ou palpebrales |
DE69602087T2 (de) * | 1995-02-22 | 1999-09-09 | Novartis Ag | 1-aryl-2-acylamino-ethan-verbindungen und ihre verwendung als neurokinin- insbesondere als neurokinin-1-antagonisten |
RU2156250C2 (ru) * | 1995-04-24 | 2000-09-20 | Новартис Аг | Производные хромона, способ их получения и фармацевтическая композиция |
US6288225B1 (en) | 1996-05-09 | 2001-09-11 | Pfizer Inc | Substituted benzolactam compounds as substance P antagonists |
WO1997003066A1 (en) * | 1995-07-07 | 1997-01-30 | Pfizer Pharmaceuticals Inc. | Substituted benzolactam compounds as substance p antagonists |
NZ321575A (en) * | 1995-10-30 | 1999-05-28 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives |
WO1997017957A1 (en) * | 1995-11-13 | 1997-05-22 | Smithkline Beecham Corporation | Hemoregulatory compounds |
FR2741262B1 (fr) | 1995-11-20 | 1999-03-05 | Oreal | Utilisation d'un antagoniste de tnf-alpha pour le traitement des rougeurs cutanees d'origine neurogene |
TW531537B (en) | 1995-12-27 | 2003-05-11 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives |
DE69720709T2 (de) | 1996-04-12 | 2004-03-11 | Janssen Pharmaceutica N.V. | Substituierte tetracyclische tetrahydrofuranderivate |
WO1997045119A1 (en) * | 1996-05-24 | 1997-12-04 | Novartis Ag | Use of substance p antagonists for treating social phobia |
MY132550A (en) * | 1996-08-22 | 2007-10-31 | Novartis Ag | Acylaminoalkenylene-amide derivatives as nk1 and nk2 antogonists |
EE04375B1 (et) * | 1996-09-10 | 2004-10-15 | Dr. Karl Thomae Gmbh | Modifitseeritud aminohapped, neid ühendeid sisaldavad ravimid ja nende valmistamise meetod |
WO1998024445A1 (en) * | 1996-12-02 | 1998-06-11 | Merck Sharp & Dohme Limited | Use of nk-1 receptor antagonists for treating schizophrenic disorders |
US6100256A (en) * | 1996-12-02 | 2000-08-08 | Merck Sharp & Dohme Ltd. | Use of NK-1 receptors antagonists for treating schizophrenic disorders |
AU744261B2 (en) * | 1997-04-24 | 2002-02-21 | Merck Sharp & Dohme Limited | Use of NK-1 receptor antagonists for treating eating disorders |
GB9716463D0 (en) * | 1997-08-04 | 1997-10-08 | Merck Sharp & Dohme | Therapeutic agents |
GB9716457D0 (en) * | 1997-08-04 | 1997-10-08 | Merck Sharp & Dohme | Therapeutic agents |
AU737019B2 (en) * | 1997-08-04 | 2001-08-09 | Merck Sharp & Dohme Limited | Use of NK-1 receptor antagonists for treating aggressive behaviour disorders |
AU738047B2 (en) * | 1997-08-04 | 2001-09-06 | Merck Sharp & Dohme Limited | Use of NK-1 receptor antagonists for treating mania |
US6319920B1 (en) | 1998-02-27 | 2001-11-20 | Syntex (U.S.A.) Llc | 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives |
DZ2769A1 (fr) * | 1998-04-17 | 2003-12-01 | Lilly Co Eli | Composés tricycliques substitués. |
AR018376A1 (es) * | 1998-05-26 | 2001-11-14 | Novartis Ag | Composiciones farmaceuticas que se pueden dispersar de una manera espontanea y el uso de las mismas para la manufactura de un medicamento |
FR2780057B1 (fr) * | 1998-06-18 | 2002-09-13 | Sanofi Sa | Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant |
GB9816897D0 (en) * | 1998-08-04 | 1998-09-30 | Merck Sharp & Dohme | Therapeutic use |
CN1216598C (zh) * | 1998-08-25 | 2005-08-31 | 诺瓦提斯公司 | 药物用途 |
US6313097B1 (en) | 1999-03-02 | 2001-11-06 | Boehringer Ingelheim Pharma Kg | Antagonists of calcitonin gene-related peptide |
WO2000071538A2 (en) * | 1999-05-21 | 2000-11-30 | Pfizer Products Inc. | 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives |
GB9917408D0 (en) * | 1999-07-23 | 1999-09-22 | Smithkline Beecham Plc | Compounds |
GB9917406D0 (en) | 1999-07-23 | 1999-09-22 | Smithkline Beecham Plc | Compounds |
US7163949B1 (en) | 1999-11-03 | 2007-01-16 | Amr Technology, Inc. | 4-phenyl substituted tetrahydroisoquinolines and use thereof |
MXPA02004330A (es) | 1999-11-03 | 2004-07-30 | Albany Molecular Res Inc | Tetrahidroisoquinolinas aril-y heteroaril-sustituidas y uso de las mismas para bloquear la recaptacion de norepinefrina, dopamina y serotonina.. |
CA2395714A1 (en) | 1999-12-21 | 2001-06-28 | Takeda Chemical Industries, Ltd. | Novel tachykinin-like polypeptides and use thereof |
NZ523456A (en) | 2000-07-11 | 2004-11-26 | Albany Molecular Res Inc | Novel 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof |
WO2002008224A1 (en) | 2000-07-26 | 2002-01-31 | Smithkline Beecham P.L.C. | Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity |
GB0101577D0 (en) | 2001-01-22 | 2001-03-07 | Smithkline Beecham Plc | Compounds |
SI1379520T1 (sl) | 2001-02-23 | 2006-08-31 | Merck & Co Inc | N-substituirani nonaril-heterociklicni NMDA/NR2B antagonisti |
WO2002080928A1 (en) | 2001-04-03 | 2002-10-17 | Merck & Co., Inc. | N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists |
GB0112836D0 (en) | 2001-05-25 | 2001-07-18 | Smithkline Beecham Plc | Medicaments |
WO2003048125A1 (en) * | 2001-12-03 | 2003-06-12 | F. Hoffmann-La Roche Ag | Aminotetralin derivatives as muscarinic receptor antagonists |
WO2003064431A2 (en) * | 2002-01-29 | 2003-08-07 | Glaxo Group Limited | Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them |
WO2003064421A1 (en) | 2002-01-29 | 2003-08-07 | Glaxo Group Limited | Aminopiperidine derivatives |
WO2003066589A1 (en) * | 2002-02-08 | 2003-08-14 | Glaxo Group Limited | Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases |
GB0203020D0 (en) | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
TWI283241B (en) | 2002-05-29 | 2007-07-01 | Tanabe Seiyaku Co | Novel piperidine compound |
JP2004285038A (ja) * | 2002-05-31 | 2004-10-14 | Takeda Chem Ind Ltd | ピペリジン誘導体、その製造法および用途 |
AR040336A1 (es) | 2002-06-26 | 2005-03-30 | Glaxo Group Ltd | Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para preparar dicho compuesto |
GB0220953D0 (en) * | 2002-09-10 | 2002-10-23 | Novartis Ag | Organic compounds |
JO2485B1 (en) | 2002-12-23 | 2009-01-20 | شركة جانسين فارماسوتيكا ان. في | 1-Piperidine-3-Yl-4-Piperidine-4-Yl-Piperazine derivatives substituted and used as quinine antagonists |
ES2282731T3 (es) | 2002-12-23 | 2007-10-16 | Janssen Pharmaceutica N.V. | Derivados de 1-piperidin-4-il-4-azetidin-3-il-piperazina sustituida y su uso como antagonistas de neuroquininas. |
JO2696B1 (en) | 2002-12-23 | 2013-03-03 | شركة جانسين فارماسوتيكا ان. في | Derivatives of 1-piperdine-4-yl-4-biprolidine-3-yl-piperazine substituted and used as quinine antagonists |
ES2310260T3 (es) | 2002-12-23 | 2009-01-01 | Janssen Pharmaceutica Nv | Derivados sustituidos de 4-(4-piperidin-4-il-piperazin-1-il)-azepan y su uso como antagonistas de la neuroquinina. |
US7592360B2 (en) | 2003-06-04 | 2009-09-22 | Merck & Co., Inc. | 3-fluoro-piperidines as NMDA/NR2B antagonists |
KR100877641B1 (ko) | 2003-11-28 | 2009-01-09 | 미쓰비시 타나베 파마 코퍼레이션 | 피페리딘 화합물 및 그의 제조 방법 |
MY142362A (en) | 2004-01-29 | 2010-11-30 | Otsuka Pharma Co Ltd | Pharmaceutical composition for promoting angiogenesis |
US7232831B2 (en) * | 2004-03-22 | 2007-06-19 | Mediquest Therapeutics, Inc. | Tetrahydro-β-carboline compounds and use thereof |
US7541357B2 (en) | 2004-07-15 | 2009-06-02 | Amr Technology, Inc. | Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
JP5078869B2 (ja) | 2005-03-08 | 2012-11-21 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ニューロキニン(nk1)拮抗物質としてのジアザ−スピロ−[4.4]−ノナン誘導体 |
ATE550019T1 (de) | 2005-05-17 | 2012-04-15 | Merck Sharp & Dohme | Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs |
GEP20125566B (en) | 2005-07-15 | 2012-07-10 | Amr Technology Inc | Aryl-and heteroaryl-substituded tetrahydro-benzazepines and use thereof to block reuptake of norepinephrine, dopamine and serotonin |
GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
GB0607532D0 (en) * | 2006-04-13 | 2006-05-24 | Novartis Ag | Organic compounds |
PL2049517T3 (pl) * | 2006-07-20 | 2014-06-30 | Novartis Ag | Pochodne amino-piperydyny jako inhibitory CETP |
US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
JP4611444B2 (ja) | 2007-01-10 | 2011-01-12 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | ポリ(adp−リボース)ポリメラーゼ(parp)阻害剤としてのアミド置換インダゾール |
WO2008090114A1 (en) | 2007-01-24 | 2008-07-31 | Glaxo Group Limited | Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-) |
EP3103791B1 (en) | 2007-06-27 | 2018-01-31 | Merck Sharp & Dohme Corp. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
AR071997A1 (es) | 2008-06-04 | 2010-07-28 | Bristol Myers Squibb Co | Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina |
US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
UA105182C2 (ru) | 2008-07-03 | 2014-04-25 | Ньюрексон, Інк. | Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность |
CA2745866A1 (en) * | 2008-12-23 | 2010-07-01 | F.Hoffmann-La Roche Ag | Dihydropyridone ureas as p2x7 modulators |
WO2010114780A1 (en) | 2009-04-01 | 2010-10-07 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
PE20120373A1 (es) | 2009-05-12 | 2012-05-17 | Albany Molecular Res Inc | 7-([1,2,4]triazolo[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina |
WO2010132487A1 (en) | 2009-05-12 | 2010-11-18 | Bristol-Myers Squibb Company | CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF |
CN102458123A (zh) | 2009-05-12 | 2012-05-16 | 阿尔巴尼分子研究公司 | 芳基、杂芳基和杂环取代的四氢异喹啉及其用途 |
JP5099731B1 (ja) | 2009-10-14 | 2012-12-19 | メルク・シャープ・アンド・ドーム・コーポレーション | p53活性を増大する置換ピペリジン及びその使用 |
US8518907B2 (en) | 2010-08-02 | 2013-08-27 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA) |
DK2606134T3 (da) | 2010-08-17 | 2019-07-22 | Sirna Therapeutics Inc | RNA-Interferens-formidlet inhibering af hepatitis-B-virus (HBV)-genekspression ved hjælp af kort interfererende nukleinsyre (siNA) |
EP2608669B1 (en) | 2010-08-23 | 2016-06-22 | Merck Sharp & Dohme Corp. | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS |
WO2012030685A2 (en) | 2010-09-01 | 2012-03-08 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
US9242981B2 (en) | 2010-09-16 | 2016-01-26 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel ERK inhibitors |
DK2632472T3 (en) | 2010-10-29 | 2018-03-19 | Sirna Therapeutics Inc | RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA) |
EP2654748B1 (en) | 2010-12-21 | 2016-07-27 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as erk inhibitors |
US20140045847A1 (en) | 2011-04-21 | 2014-02-13 | Piramal Enterprises Limited | Crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation |
WO2013063214A1 (en) | 2011-10-27 | 2013-05-02 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
EP3358013B1 (en) | 2012-05-02 | 2020-06-24 | Sirna Therapeutics, Inc. | Short interfering nucleic acid (sina) compositions |
RU2660429C2 (ru) | 2012-09-28 | 2018-07-06 | Мерк Шарп И Доум Корп. | Новые соединения, которые являются ингибиторами erk |
AU2013352568B2 (en) | 2012-11-28 | 2019-09-19 | Merck Sharp & Dohme Llc | Compositions and methods for treating cancer |
ES2707305T3 (es) | 2012-12-20 | 2019-04-03 | Merck Sharp & Dohme | Imidazopiridinas sustituidas como inhibidores de HDM2 |
WO2014120748A1 (en) | 2013-01-30 | 2014-08-07 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as hdm2 inhibitors |
WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
EP3706742B1 (en) | 2017-11-08 | 2023-03-15 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
EP3833667B1 (en) | 2018-08-07 | 2024-03-13 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
WO2020033282A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
CA3205097A1 (en) * | 2021-01-14 | 2022-07-21 | Jason Allan Wiles | Macrocycle complement factor b inhibitors |
CA3220039A1 (en) | 2021-06-14 | 2022-12-22 | Jr. David St. Jean | Urea derivatives which can be used to treat cancer |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX18467A (es) * | 1988-11-23 | 1993-07-01 | Pfizer | Agentes terapeuticos de quinuclidinas |
US5145967A (en) * | 1989-04-20 | 1992-09-08 | Anaquest, Inc. | Method for preparing 4-alkoxyalkyl-4-phenylaminopiperdines and derivatives thereof |
IE903957A1 (en) * | 1989-11-06 | 1991-05-08 | Sanofi Sa | Aromatic amine compounds, their method of preparation and¹pharmaceutical compositions in which they are present |
FR2654725B1 (fr) * | 1989-11-23 | 1992-02-14 | Rhone Poulenc Sante | Nouveaux derives de l'isoindolone, leur preparation et les compositions pharmaceutiques qui les contiennent. |
US5126455A (en) * | 1989-12-13 | 1992-06-30 | Glaxo Inc. | Preparation of substituted alkali metal piperidine-4-carboxylates |
HU226529B1 (en) * | 1990-05-31 | 2009-03-30 | Pfizer | Process for preparing substituted piperidines |
EP0532527B1 (en) * | 1990-06-01 | 1994-11-09 | Pfizer Inc. | 3-amino-2-aryl quinuclidines, process for their preparation and pharmaceutical compositions containing them |
DK0550635T3 (da) * | 1990-09-28 | 1995-09-04 | Pfizer | Cykliske forbindelser med kondeserede ringe, som er analoger til nitrogenholdige ikke-aromatiske het erocykliske forbindelser |
-
1992
- 1992-07-27 MY MYPI92001339A patent/MY110227A/en unknown
- 1992-07-30 PH PH44743A patent/PH29963A/en unknown
- 1992-08-01 TW TW081106123A patent/TW204342B/zh not_active IP Right Cessation
- 1992-08-04 DE DE59201771T patent/DE59201771D1/de not_active Expired - Lifetime
- 1992-08-04 AT AT92810594T patent/ATE120456T1/de active
- 1992-08-04 DK DK92810594.9T patent/DK0532456T3/da active
- 1992-08-04 ES ES92810594T patent/ES2070617T3/es not_active Expired - Lifetime
- 1992-08-04 EP EP92810594A patent/EP0532456B1/de not_active Expired - Lifetime
- 1992-08-10 FI FI923575A patent/FI104631B/fi not_active IP Right Cessation
- 1992-08-10 AU AU20965/92A patent/AU660180B2/en not_active Ceased
- 1992-08-10 CA CA002075684A patent/CA2075684C/en not_active Expired - Fee Related
- 1992-08-10 MX MX9204627A patent/MX9204627A/es unknown
- 1992-08-10 NZ NZ243888A patent/NZ243888A/en unknown
- 1992-08-10 IL IL10276992A patent/IL102769A/en not_active IP Right Cessation
- 1992-08-11 US US07/929,186 patent/US5310743A/en not_active Expired - Lifetime
- 1992-08-11 JP JP04214093A patent/JP3118090B2/ja not_active Expired - Fee Related
- 1992-08-11 ZA ZA926013A patent/ZA926013B/xx unknown
- 1992-08-11 NO NO923123A patent/NO303448B1/no not_active IP Right Cessation
- 1992-08-11 RU SU5052784A patent/RU2114829C1/ru active
- 1992-08-11 HU HU9202615A patent/HU221305B1/hu not_active IP Right Cessation
- 1992-08-11 KR KR1019920014407A patent/KR100261367B1/ko not_active IP Right Cessation
-
1994
- 1994-03-30 SA SA94140632A patent/SA94140632A/ar unknown
- 1994-04-04 US US08/196,360 patent/US5541195A/en not_active Expired - Lifetime
-
1995
- 1995-04-28 GR GR950401075T patent/GR3015954T3/el unknown
- 1995-06-07 US US08/482,704 patent/US5646144A/en not_active Expired - Lifetime
-
1996
- 1996-06-27 IL IL11875096A patent/IL118750A0/xx unknown
-
1997
- 1997-07-04 NO NO973117A patent/NO973117D0/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5310743A (en) | 1-acylpiperidine compounds | |
EP0930298B1 (en) | Fluorinated 1,4-disubstituted piperidine derivatives | |
JP3014367B2 (ja) | Ccr−3受容体アンタゴニスト | |
AU705851B2 (en) | Aroyl-piperidine derivatives | |
US20040006081A1 (en) | Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity | |
JP4918477B2 (ja) | 1−アミノ−フタラジン誘導体、これらの調製及び治療的使用 | |
US7053078B2 (en) | Serine protease inhibitors | |
JP2003502314A (ja) | 化合物 | |
US5705505A (en) | Cyclic amide derivatives for treating asthma | |
CA2237971C (en) | Substituted 4-(1h-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases | |
JP2005510522A (ja) | ピペリジン誘導体およびケモカイン・レセプター(特にccr5)活性モジュレーターとしてのその使用 | |
JPH10513191A (ja) | タキキニン受容体アンタゴニストとしての5−(4−置換−ピペリジニル−1)−3−アリール−ペンタン酸誘導体 | |
JP4153574B2 (ja) | 新規なピペリジン誘導体、その製造法およびそれを含有する循環器官用剤 | |
JP2001524466A (ja) | ニューロキニンアンタゴニストとしての置換されたオキシム | |
JPWO2005030722A1 (ja) | N−置換−n−(4−ピペリジニル)アミド誘導体 | |
JP3282618B2 (ja) | 含フッ素1,4−ジ置換ピペリジン誘導体の新規製造中間体 | |
JP3282617B2 (ja) | 含フッ素1,4−ジ置換ピペリジン誘導体の新規製造中間体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
EXP | Patent expired |